A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer

被引:132
作者
Suidan, Rudy S. [1 ,2 ]
Ramirez, Pedro T. [2 ]
Sarasohn, Debra M. [3 ]
Teitcher, Jerrold B. [3 ]
Iyer, Revathy B. [4 ]
Zhou, Qin [5 ]
Iasonos, Alexia [5 ]
Denesopolis, John [1 ]
Zivanovic, Oliver [1 ,6 ]
Roche, Kara C. Long [1 ,6 ]
Sonoda, Yukio [1 ,6 ]
Coleman, Robert L. [2 ]
Abu-Rustum, Nadeem R. [1 ,6 ]
Hricak, Hedvig [3 ]
Chi, Dennis S. [1 ,6 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, 1275 York Ave, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, MDACC, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA
[3] MSKCC, Dept Radiol, New York, NY USA
[4] MDACC, Dept Radiol, Houston, TX USA
[5] MSKCC, Dept Epidemiol & Biostat, New York, NY USA
[6] Weill Cornell Med Coll, New York, NY USA
关键词
Ovarian cancer; CT scan; CA-125; Primary debulking; Gross residual disease; GYNECOLOGIC-ONCOLOGY; STAGE-III; CYTOREDUCTIVE SURGERY; FALLOPIAN-TUBE; SERUM CA-125; CARCINOMA; PACLITAXEL; CISPLATIN; MODEL; TRIAL;
D O I
10.1016/j.ygyno.2017.02.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To assess the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease (RD) at primary cytoreduction in advanced ovarian cancer. Methods. A prospective, non-randomized, multicenter trial of patients who underwent primary debulking for stage III-IV epithelial ovarian cancer previously identified 9 criteria associated with suboptimal (>1 cm residual) cytoreduction. This is a secondary post-hoc analysis looking at the ability to predict any RD. Four clinical and 18 radiologic criteria were assessed, and a multivariate model predictive of RD was developed. Results. From 7/2001-12/2012, 350 patients met eligibility criteria. The complete gross resection rate was 33%. On multivariate analysis, 3 clinical and 8 radiologic criteria were significantly associated with the presence of any RD: age >= 60 years (OR = 1.5); CA-125 >= 600 U/mL (OR = 1.3); ASA 3-4 (OR = 1.6); lesions in the root of the superior mesenteric artery (OR = 4.1), splenic hilum/ligaments (OR = 1.4), lesser sac > 1 cm (OR = 2.2), gastrohepatic ligament/porta hepatis (OR = 1.4), gallbladder fossa/intersegmental fissure (OR = 2); suprarenal retroperitoneal lymph nodes (OR = 1.3); small bowel adhesions/thickening (OR = 1.1); and moderate-severe ascites (OR = 2.2). All ORs were significant with p < 0.01. A 'predictive score' was assigned to each criterion based on its multivariate OR, and the rate of having any RD for patients who had a total score of 0-2, 3-5, 6-8, and >= 9 was,45%, 68%, 87%, and 96%, respectively. Conclusions. We identified 11 criteria associated with RD, and developed a predictive model in which the rate of having any RD was directly proportional to a predictive score. This model may be helpful in treatment planning. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:27 / 31
页数:5
相关论文
共 21 条
  • [1] Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Armstrong, DK
    Bundy, B
    Wenzel, L
    Huang, HQ
    Baergen, R
    Lele, S
    Copeland, LJ
    Walker, JL
    Burger, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) : 34 - 43
  • [2] Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer
    Axtell, Allison E.
    Lee, Margaret H.
    Bristow, Robert E.
    Dowdy, Sean C.
    Cliby, William A.
    Raman, Steven
    Weaver, John P.
    Gabbay, Mojan
    Ngo, Michael
    Lentz, Scott
    Cass, Ilana
    Li, Andrew J.
    Karlan, Beth Y.
    Holschneider, Christine H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (04) : 384 - 389
  • [3] Bristow RE, 2000, CANCER, V89, P1532, DOI 10.1002/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO
  • [4] 2-A
  • [5] Adherence to Treatment Guidelines for Ovarian Cancer as a Measure of Quality Care
    Bristow, Robert E.
    Chang, Jenny
    Ziogas, Argyrios
    Anton-Culver, Hoda
    [J]. OBSTETRICS AND GYNECOLOGY, 2013, 121 (06) : 1226 - 1234
  • [6] Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis
    Chang, Suk-Joon
    Hodeib, Melissa
    Chang, Jenny
    Bristow, Robert E.
    [J]. GYNECOLOGIC ONCOLOGY, 2013, 130 (03) : 493 - 498
  • [7] What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Chi, D. S.
    Eisenhauer, E. L.
    Lang, J.
    Huh, J.
    Haddad, L.
    Abu-Rustum, N. R.
    Sonoda, Y.
    Levine, D. A.
    Hensley, M.
    Barakat, R. R.
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 559 - 564
  • [8] A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma
    Chi, Dennis S.
    Zivanovic, Oliver
    Palayekar, Meena J.
    Elsenhauer, Eric L.
    Abu-Rustum, Nadeern R.
    Sonoda, Yukio
    Levine, Douglas A.
    Leltao, Manio M.
    Brown, Carol L.
    Barakat, Richard R.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 112 (01) : 6 - 10
  • [9] Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach
    Chi, DS
    Franklin, CC
    Levine, DA
    Akselrod, F
    Sabbatini, P
    Jarnagin, WR
    DeMatteo, R
    Poynor, EA
    Abu-Rustum, NR
    Barakat, RR
    [J]. GYNECOLOGIC ONCOLOGY, 2004, 94 (03) : 650 - 654
  • [10] The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma
    Dowdy, SC
    Mullany, SA
    Brandt, KR
    Huppert, BJ
    Cliby, WA
    [J]. CANCER, 2004, 101 (02) : 346 - 352